Lui Franciosi, PhD
Dr. Franciosi has more than 20 years of experience conducting pharmaceutical and medical device studies in academia and industry. Previously, he acted as the Chief Operating Officer at Verona Pharma PLC, London Stock Exchange (AIM: VRP). Prior to Verona Pharma, Dr. Franciosi completed his post-doctoral research in COPD progression modeling at the Clinical Pharmacology & Discovery Medicine Unit, GlaxoSmithKline, UK. He obtained his Doctorate & Masters degrees at The University of British Columbia (UBC), Canada – and pursued business studies at the University of Warwick, UK. He is currently an adjunct professor at UBC Faculty of Medicine, Department of Anesthesiology, Pharmacology & Therapeutics.
Michael J. A. Walker, PhD
Dr. Walker received his pharmacology training at the University of London which, included a period of drug discovery training at Pfizer Ltd., (UK). His main focus has been in the discovery of drugs, whether naturally occurring or not, and in the process of drug discovery itself. His commitment to his industry includes 43 years at UBC and numerous contributions to universities around the world. Over the past 25 years, Dr. Walker was the founder or co-founder of eight different drug discovery companies, both public and private, including Cardiome Pharma (TSX:COM) in Canada and Verona Pharma Ltd. in London. Additionally, Dr. Walker has researched and published numerous, journals, periodicals, conference presentations, and other related publications.